{
    "doi": "https://doi.org/10.1182/blood.V116.21.2389.2389",
    "start_url": "https://ashpublications.org/blood/search-results?sort=Date+-+Oldest+First&f_ArticleTypeDisplayName=Meeting+Report&fl_SiteID=1000001&page=1864",
    "start_url_page_num": 1864,
    "is_scraped": "1",
    "article_title": "Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005 ",
    "article_date": "November 19, 2010",
    "session_type": "Clinical Results - Autologous Transplantation: Poster II",
    "abstract_text": "Abstract 2389 Autologous hematopoietic cell transplantation (autoHCT) is standard therapy for high-risk hematologic disorders and solid tumors. We assessed whether overall survival (OS) at Day 100, which represents early transplant-related mortality (TRM), and at one year, which represents disease-related mortality and later TRM, had changed over time. The study population was derived from patients undergoing 68,404 first autoHCTs between 1994\u20132005 in US and Canadian centers reported to the CIBMTR. Statistical significance was measured using P trend over 6 time cohorts to test whether the OS estimates were stable (slope = 0), increasing (slope>0) or decreasing (slope<0) over time. The Day 100 and 1-year OS estimates are shown in the Table . Disease and disease status subgroups were defined a priori , and the OS estimates are not adjusted for any covariates such as age, Karnofsky status, etc. Mortality rates at Day 100 were, in general, low for all diseases examined and improved significantly over time for NHL in complete remission (CR) 2/sensitive 1 st relapse, for lymphoma in primary induction failure (no prior complete remission) and myeloma in first partial or complete remission. Improvements in 1-year OS were seen for NHL in CR1/sensitive 1 st relapse and myeloma in remission at the time of transplant. OS has improved for many patients undergoing autoHCT which likely reflects improvement in supportive care and better patient selection. Day 100 mortality rates in autoHCT patients treated during the most recent period 2004-5 are as low as 2\u20135% in patients with chemotherapy sensitive disease pre-autoHCT. Even in patients transplanted with resistant disease (no prior CR), the Day 100 mortality rate is only 5% in MM and 9% in HL/NHL patients. Although the 1-year OS has improved over time there is still a significant decline in OS between the Day 100 and 1-year time points, especially for patients with NHL in CR2/sensitive 1 st relapse, lymphoma in primary induction failure and myeloma not in remission, suggesting a need for improved disease control in these patients. Table 1: Overall survival (95% CI) estimates over time.  Autologous HCT . 1994-5 . 1996-7 . 1998-9 . 2000-01 . 2002-3 . 2004-5 . P trend . NHL in CR2/Rel 1 sens  N  890  1067  1041  1020  946  1116  <0.001  @100 days  89 (87\u201391)  90 (88\u201392)  90 (88\u201392)  94 (92\u201395)  94 (92\u201395)  95 (94\u201397)  <0.001  @1 year  68 (65\u201371)  69 (66\u201372)  72 (69\u201375)  77 (75\u201380)  78 (75\u201380)  80 (77\u201383)   HL in CR2/Rel1 sens N  384  384  466  435  477  573  0.4758  @100 days 95 (92\u201397)  95 (92\u201397)  96 (94\u201397)  97 (95\u201398)  96 (94\u201398)  97 (95\u201398)  0.1985  @1 year  86 (82\u201389)  87 (84\u201391)  87 (83\u201390)  89 (85\u201392)  90 (87\u201393)  91 (88\u201393)   HL or NHL in PIF N  647  708  772  895  570  504  0.0299  @100 days  86 (84\u201389)  88 (86\u201390)  87 (84\u201389)  90 (87\u201392)  90 (88\u201393)  91 (89\u201394)  0.7532  @1 year  69 (65\u201373)  69 (65\u201372)  70 (67\u201374)  72 (68\u201375)  71 (67\u201375)  72 (67\u201376)   MM in CR1/PR1/PIF sens N  267  541  718  1567  2423  3192  <0.001  @100 days  96 (94\u201398)  96 (94\u201398)  96 (94\u201397)  97 (96\u201398)  98 (97\u201398)  98 (98\u201399)  <0.001  @1 year  83 (79\u201388)  84 (81\u201387)  87 (85\u201390)  90 (89\u201392)  92 (91\u201393)  92 (91\u201393)   MM in less than PR N  105  177  392  420  521  586  0.3829  @100 days  92 (85\u201396)  94 (90\u201397)  96 (94\u201398)  96 (94\u201398)  97 (95\u201398)  95 (93\u201397)  0.0857  @1 year  79 (70\u201387)  79 (73\u201385)  86 (82\u201389)  88 (84\u201391)  88 (85\u201391)  87 (84\u201390)   Autologous HCT . 1994-5 . 1996-7 . 1998-9 . 2000-01 . 2002-3 . 2004-5 . P trend . NHL in CR2/Rel 1 sens  N  890  1067  1041  1020  946  1116  <0.001  @100 days  89 (87\u201391)  90 (88\u201392)  90 (88\u201392)  94 (92\u201395)  94 (92\u201395)  95 (94\u201397)  <0.001  @1 year  68 (65\u201371)  69 (66\u201372)  72 (69\u201375)  77 (75\u201380)  78 (75\u201380)  80 (77\u201383)   HL in CR2/Rel1 sens N  384  384  466  435  477  573  0.4758  @100 days 95 (92\u201397)  95 (92\u201397)  96 (94\u201397)  97 (95\u201398)  96 (94\u201398)  97 (95\u201398)  0.1985  @1 year  86 (82\u201389)  87 (84\u201391)  87 (83\u201390)  89 (85\u201392)  90 (87\u201393)  91 (88\u201393)   HL or NHL in PIF N  647  708  772  895  570  504  0.0299  @100 days  86 (84\u201389)  88 (86\u201390)  87 (84\u201389)  90 (87\u201392)  90 (88\u201393)  91 (89\u201394)  0.7532  @1 year  69 (65\u201373)  69 (65\u201372)  70 (67\u201374)  72 (68\u201375)  71 (67\u201375)  72 (67\u201376)   MM in CR1/PR1/PIF sens N  267  541  718  1567  2423  3192  <0.001  @100 days  96 (94\u201398)  96 (94\u201398)  96 (94\u201397)  97 (96\u201398)  98 (97\u201398)  98 (98\u201399)  <0.001  @1 year  83 (79\u201388)  84 (81\u201387)  87 (85\u201390)  90 (89\u201392)  92 (91\u201393)  92 (91\u201393)   MM in less than PR N  105  177  392  420  521  586  0.3829  @100 days  92 (85\u201396)  94 (90\u201397)  96 (94\u201398)  96 (94\u201398)  97 (95\u201398)  95 (93\u201397)  0.0857  @1 year  79 (70\u201387)  79 (73\u201385)  86 (82\u201389)  88 (84\u201391)  88 (85\u201391)  87 (84\u201390)   View Large NHL \u2013 non-Hodgkin lymphoma, HL \u2013 Hodgkin lymphoma, MM \u2013 myeloma, CR \u2013 complete remission, Rel \u2013 relapse, PIF \u2013 primary induction failure, sens \u2013 sensitive Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "hematopoietic stem cell transplantation",
        "complete remission",
        "multiple myeloma",
        "disease remission",
        "lymphoma",
        "transplantation",
        "chemotherapy regimen",
        "hematological diseases",
        "hodgkin's disease",
        "lymphoma, non-hodgkin"
    ],
    "author_names": [
        "Philip L. McCarthy, MD",
        "Theresa Hahn, PhD",
        "Anna Hassebroek, MPH",
        "John P. Klein, Ph.D.",
        "J. Douglas Rizzo, MD, MS",
        "Susan Parsons, MD, MRP",
        "Steven Joffe, MD, MPH",
        "Navneet S. Majhail, MD, MS"
    ],
    "author_affiliations": [
        [
            "BMT Program, Roswell Park Cancer Institute, Buffalo, NY, USA, "
        ],
        [
            "Dept. of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA, "
        ],
        [
            "Center for International Blood and Marrow Transplant Research, Minneapolis, MN, "
        ],
        [
            "Department of Biostatistics, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, "
        ],
        [
            "Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, "
        ],
        [
            "Tufts Medical Center, Boston, MA, "
        ],
        [
            "Dana-Farber Cancer Institute, Boston, MA, "
        ],
        [
            "Hematology and Oncology (IM) Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA"
        ]
    ],
    "first_author_latitude": "42.898701599999995",
    "first_author_longitude": "-78.86554819999999"
}